Glenmark Shares Up After USFDA Nod To Sell Rufinamide

Subscribe to GoodReturns
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

    Shares in Glenmark Pharmaceuticals were trading marginally higher after the company said that it has been granted tentative approval by the US health regulator to sell Rufinamide, which is used to treat seizures caused by Lennox-Gastaut syndrome.

    Glenmark Shares Up After USFDA Nod To Sell Rufinamide
    Glenmark Pharmaceuticals: Quotes, News
    BSE 674.00BSE Quote13.9 (2.06%)
    NSE 676.20NSE Quote15.1 (2.23%)
    The stock was last trading at Rs 899 on the National Stock Exchange. Lennox-Gastaut syndrome is a form of childhood-onset epilepsy.

    "Glenmark...has been granted tentative approval last week by the United States Food and Drug Administration (USFDA) for its Rufinamide tablets," the company said in a BSE filing.

    The approval has been granted for the tablets in 200 mg and 400 mg strengths. Rufinamide is a therapeutic equivalent of Banzel tablets of Eisai.

    Glenmark further said: "Under the terms of a settlement agreement between Glenmark and Eisai, Glenmark will be permitted to market this product in the US on May 30, 2022 or potentially earlier under certain circumstances."

    GoodReturns.in

    Read more about: glenmark
    Story first published: Thursday, May 21, 2015, 12:24 [IST]
    Company Search
    Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

    Find IFSC

    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more